ALK in complex with lorlatinib with in-silico mutated residues

PyMol session file (.pse) files of the structure of ALK in complex with lorlatinib (original PDB accession 4CLJ) with <i>in-silico</i> mutated residues as reported in figure 4. Computational mutagenesis was applied to residues known to confer resistance to TKIs in order to highlight their potential impact on drug binding and efficacy. The mutated residues are represented simultaneously for illustrative purposes.